Pre-Open Stock Movers

TAT Technologies (NASDAQ: TATT) 54.2% HIGHER; TAT and Honeywell International, Inc., (NYSE: HON) announced today a 10-year agreement to support the global MRO activities for the GTCP331-200/250 auxiliary power unit (the “331 APU”).

Colony Capital, Inc. (NYSE: CLNY) 13.3% HIGHER; entered into a definitive agreement to sell six of its hospitality portfolios to Highgate, a premier real estate investment and hospitality management company, in a transaction valued at $2.8 billion, including $67.5 million of gross proceeds on a consolidated basis and the assumption of $2.7 billion in consolidated investment-level debt. The six portfolios consist of 22,676 rooms across 197 hotel properties.

Endo International plc (NASDAQ: ENDP) 9.6% HIGHER; announced that its subsidiary, Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax' COVID-19 vaccine candidate.

Luminex Corporation (NASDAQ: LMNX) 6.7% HIGHER; received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, to conduct product development work and complete a 510(k) filing for Luminex's expanded NxTAG® Respiratory Pathogen Panel (RPP), which includes the SARS-CoV-2 virus for high-throughput COVID-19 testing. This effort will help address the continuing long-term need for cost-effective, multiplex diagnostic tests that can differentiate COVID-19 from current strains of other common respiratory illnesses, such as flu.

Novavax, Inc. (Nasdaq: NVAX) 6.4% HIGHER; initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax COVID-19 vaccine candidate. The trial is being conducted in the United Kingdom (UK), in partnership with the UK Governments Vaccines Taskforce, and is expected to enroll and immunize up to 10,000 individuals between 18-84 (inclusive) years of age, with and without relevant comorbidities, over the next four to six weeks.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) 5.2% HIGHER; upgraded at Barclays

Carnival (NYSE: CCL) 4.7% HIGHER; upgraded at Barclays

IBEX Limited (NASDAQ: IBEX) 4.2% LOWER; reported Q4 EPS of $0.14, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $100.9 million versus the consensus estimate of $96.24 million.

Royal Caribbean (NYSE: RCL) 3.5% HIGHER; upgraded at Barclays

Penn National Gaming, Inc. (Nasdaq: PENN) 2.8% LOWER; announced that it has priced its underwritten public offering of 14,000,000 shares of its common stock, $0.01 par value per share, at a public offering price of $61.00 per share (the Offering).

Costco (NASDAQ: COST) 1.2% LOWER; reported Q4 EPS of $3.13, $0.30 better than the analyst estimate of $2.83. Revenue for the quarter came in at $53.38 billion versus the consensus estimate of $52.08 billion. Total company comps in the quarter rose 11.4% or 14.1% adjusted. e-Commerce comps rose 90.6% or 91.3% adjusted.

Bristol Myers Squibb (NYSE: BMY) 1.2% HIGHER; today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 1% (programmed death-ligand 1). CheckMate -274 is the first and only Phase 3 trial in which immunotherapy has reduced the risk of relapse in the adjuvant setting for these patients. The safety profile of Opdivo was consistent with previously reported studies in solid tumors.

Vail Resorts (NYSE: MTN) 1.2% HIGHER; reported Q4 EPS of ($3.82), $0.39 worse than the analyst estimate of ($3.43). Revenue for the quarter came in at $77.21 million versus the consensus estimate of $140.94 million.

Calamp Corp. (NASDAQ: CAMP) 1.2% HIGHER; reported Q2 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $83.5 million versus the consensus estimate of $76.84 million.